Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa, AS Gerrie… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …
被引用次数：99 相关文章

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of Clinical …, 2019 - scholars.northwestern.edu
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …
[HTML] nih.gov

[HTML][HTML] Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

JN Gerson, E Handorf, D Villa, AS Gerrie… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

JN Gerson, E Handorf, D Villa, AS Gerrie… - Journal of Clinical …, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> Mantle cell lymphoma (MCL) is a
B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa, AS Gerrie… - Journal of Clinical …, 2019 - experts.umn.edu
PURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of Clinical …, 2019 - ohiostate.elsevierpure.com
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of Clinical …, 2019 - experts.nebraska.edu
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of Clinical …, 2019 - researchwithrutgers.com
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of Clinical …, 2019 - pure.johnshopkins.edu
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …

Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era

JN Gerson, E Handorf, D Villa… - Journal of …, 2019 - mdanderson.elsevierpure.com
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1
expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after …